BRAF mutations are well known as oncogenic drivers in several cancers and are found in approximately 6% of all cases of metastatic cancer.1 Activating BRAF mutations lead to constitutive activation of the mitogen-activated protein kinase (MAPK) pathway resulting in uncontrolled cell proliferation, dedifferentiation, and cell survival.2 The most common BRAF mutation in human cancer is the BRAF V600E mutation.3,4. Here, BRAF is linked to metastatic malignant neoplasm.